MARK2 anticorps

N° du produit ABIN1736766

Détail du produit anti-MARK2 anticorps

Antigène: MARK2 (MAP/microtubule Affinity-Regulating Kinase 2 (MARK2))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MARK2 est non-conjugé

Application: ELISA, Western Blotting (WB), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Specificité: Reacts with the N-terminus part of human MARK2

Réactivité croisée: Souris, Rat (Rattus)

Réactivité croisée (Details): Cross reacts with mouse and rat protein.

Purification: Antigen affinity purified

Immunogène: Synthetic peptide from human MARK2.

Isotype: IgG

Information d'application

Indications d'application:

Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only :
ELISA (1:20000), IF (1:100 - 1:500), IHC-P (10 μg/mL), WB (1:500 - 1:1000)

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS (without Mg2+, Ca2+), pH 7.4, NaCl 150 mM, glycerol 50 % , Sodium azide 0.02 %

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: Short term 4°C, long term aliquot and store at -20°C, avoid freeze thaw cycles.

Détails sur MARK2

Antigène: MARK2 (MAP/microtubule Affinity-Regulating Kinase 2 (MARK2))

Autre désignation: MARK2 (MARK2 Produits)

Synonymes: anticorps EMK-1, anticorps EMK1, anticorps PAR-1, anticorps Par-1b, anticorps Par1b, anticorps AU024026, anticorps Emk, anticorps Par-1, anticorps mKIAA4207, anticorps microtubule affinity regulating kinase 2, anticorps MAP/microtubule affinity regulating kinase 2, anticorps MARK2, anticorps Mark2

Sujet: MARK2 is a kinases that modulates the activity of MSTs kinases and thus regulates the Hippo pathway.

ID gène: 2011

Pathways: SARS-CoV-2 Protein Interactome, Phosphorylation & l'infection par le SRAS-CoV-2